Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 117,164 | 20,620 | 18,752 | 97,428 | 160,203 |
| Marketable Securities | 656,665 | 181,041 | 122,296 | 102,791 | 7,133 |
| Receivables | 55,992 | 25,596 | 14,700 | 6,170 | 12,634 |
| Inventories | 7,124 | 4,373 | 1,923 | 1,633 | 269 |
| Other current assets | 33,595 | 5,391 | 5,382 | 6,690 | 4,919 |
| TOTAL | $870,540 | $237,021 | $163,053 | $214,712 | $185,158 |
| Non-Current Assets | |||||
| PPE Net | 5,372 | 4,212 | 1,819 | 372 | 486 |
| Investments And Advances | 0 | 6,438 | 8,345 | 29,728 | 0 |
| Intangibles | 337,899 | 334,069 | 302,733 | 69,139 | 67,529 |
| Other Non-Current Assets | 46,992 | 89,281 | 125,635 | 189,110 | 4,856 |
| TOTAL | $390,263 | $434,000 | $438,532 | $288,349 | $72,871 |
| Total Assets | $1,260,803 | $671,021 | $601,585 | $503,061 | $258,029 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 26,433 | 224,529 | 212,910 | 201,985 | N/A |
| Accounts payable and accrued liabilities | 4,183 | 2,259 | 2,734 | 4,083 | 7,698 |
| Accrued Expenses | 19,200 | 7,377 | 6,397 | 5,405 | 4,866 |
| Other current liabilities | 29,147 | 4,703 | 5,088 | 10,414 | 7,859 |
| TOTAL | $82,249 | $238,868 | $227,129 | $222,821 | $22,779 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 195,908 |
| Deferred Revenues | 3,286 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 617,640 | 32,365 | 33,166 | 45,338 | 10,255 |
| TOTAL | $617,640 | $32,365 | $33,166 | $42,958 | $210,842 |
| Total Liabilities | $699,889 | $271,233 | $260,295 | $265,779 | $233,621 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 20,445 | 21,204 | 20,920 | 20,773 | 19,578 |
| Common Shares | 21 | 21 | 21 | 20 | 20 |
| Retained earnings | -229,197 | -400,924 | -431,127 | -429,491 | -659,315 |
| Other shareholders' equity | -1,024 | 2,486 | 2,743 | 4,903 | 3,043 |
| TOTAL | $560,914 | $399,788 | $341,290 | $237,282 | $24,408 |
| Total Liabilities And Equity | $1,260,803 | $671,021 | $601,585 | $503,061 | $258,029 |